Polio Clinical Trial
Official title:
OPV Transmissibility in Communities After Cessation of Routine OPV Immunization
The investigators propose to study both inter- and intra-household Oral Polio Vaccine (OPV) transmission in a primarily inactivated-polio vaccine (IPV)-vaccinated community in Mexico. The investigators will enroll 3 distinct clusters of households in a municipality in Orizaba, Veracruz, Mexico prior to the February 2015 National Immunization Week (NIW.) These clusters will be physically separate from one another and differ only in the proportion of OPV-eligible children who will receive OPV during the February 2015 NIW (10%, 30% and 70% vaccinated.) The investigators will look at inter-household and intra-household transmission. The investigators will then determine if epidemiologic (i.e.: degree of contact), anthropometric (i.e.: nutritional status) or clinical covariates (i.e.: IPV/OPV immunization history) are associated with intra-household transmission.
We propose a prospective study to be conducted in 3 distinct clusters of 150 households each
in one semi-urban municipality in Orizaba, Veracruz, Mexico during and after the February
2015 National Immunization Week (NIW.) Mexico provides a unique environment to study OPV
transmission. The last case of poliomyelitis was reported in 1990. Mexico transitioned from
an OPV to an IPV-based immunization regimen in 2007-2008. Currently, Mexican children receive
IPV at 2, 4, 6, and 18 months of age. In addition, children ≤5 years old who have received at
least 2 doses of IPV are eligible to receive OPV during biannual NIW held in February and May
each year. Because of the changes in vaccination regimens over time, Mexican households
consist of individuals with different degrees of susceptibility to OPV infection: those born
before 2007 who were exposed to WPV and OPV or OPV alone, those born after 2007 exposed to
IPV with intermittent OPV exposure, and un-vaccinated infants, some with maternal polio virus
antibodies. By studying OPV transmission in this setting, we will be able to assess the
impact of differing immunization status on OPV shedding and transmission.
We will conduct our study in a relatively isolated and semi-urban municipality of Orizaba,
Veracruz, Mexico. These household clusters will differ only in the proportion of OPV-eligible
children who will be OPV-vaccinated during the February 2015 National Immunization Week (10%,
30% and 70%.) We will enroll households that have at least 1 healthy child less than 5 years
of age with an up-to-date IPV vaccination history. Enrolled households will then be
randomized to the OPV-vaccinated or non-vaccinated arm of each household cluster. Eligible
children from households in the OPV-vaccinated arm will then be further randomized to either
receive OPV or remain un-vaccinated. Thus, only one child per household in the OPV-vaccinated
arm will be vaccinated.
We will collect stool samples from all members of the enrolled households serially over the
course of the study and will determine if individuals shed OPV in their stool using a
serotype-specific real-time polymerase chain reaction (PCR) assay. We will define
inter-household transmission as fecal OPV shedding by any member of a non-vaccinated
household. By comparing inter-household transmission rates among all the household clusters,
we will determine the if the proportion of OPV-vaccinated children impacts community OPV
transmission in a primarily IPV-vaccinated community. These results will be critical to
predicting the risk of OPV re-introduction in the event of a poliomyelitis outbreak in the
post-OPV era.
We will define intra-household transmission as OPV shedding by household contacts living in
vaccinated households. We will examine intra-household transmission in all clusters together
to determine if certain characteristics are associated with transmission to household
contacts. Elucidating these characteristics would allow for targeted interventions to reduce
or prevent OPV transmission as cessation policy is implemented or in the event that OPV
re-introduction is needed during polio endgame.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00772369 -
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
|
Phase 4 | |
Completed |
NCT00401531 -
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
|
Phase 3 | |
Completed |
NCT00772928 -
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
|
Phase 3 | |
Completed |
NCT00254917 -
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
|
Phase 4 | |
Completed |
NCT04576910 -
Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
|
Phase 4 | |
Completed |
NCT04264546 -
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06114810 -
Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV
|
Phase 4 | |
Completed |
NCT01475539 -
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
|
Phase 4 | |
Completed |
NCT01244464 -
A Study of the Safety of IMOVAX Polio™ in China
|
Phase 4 | |
Completed |
NCT00255047 -
Safety and Immune Response of Different Pediatric Combination Vaccines.
|
Phase 3 | |
Recruiting |
NCT05850364 -
A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine
|
Phase 3 | |
Completed |
NCT00662870 -
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
|
Phase 3 | |
Completed |
NCT03147560 -
Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants
|
Phase 4 | |
Completed |
NCT05083039 -
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
|
||
Active, not recruiting |
NCT00932269 -
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
|
Phase 0 | |
Completed |
NCT03922061 -
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
|
Phase 1 | |
Enrolling by invitation |
NCT03818477 -
Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array Card
|
||
Completed |
NCT00348387 -
Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
|
Phase 3 | |
Not yet recruiting |
NCT06460545 -
Phase IV Study of Concomitant Administration of the sIPV and HepA
|
Phase 4 | |
Active, not recruiting |
NCT01908114 -
To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan
|
Phase 4 |